Core Points - Haemonetics Corporation announced the availability of its financial results for the second quarter of fiscal year 2026, which ended on September 27, 2025 [1] - A conference call and webcast will be held on November 6, 2025, at 8:00 a.m. ET to discuss the results [1][2] - The company provides a range of medical technologies aimed at improving healthcare quality and efficiency, including hospital technologies, plasma collection technologies, and blood component collection products [2] Financial Results - The financial results for the second quarter of fiscal year 2026 will be published at 6:00 a.m. ET on November 6, 2025 [5] - Supplemental earnings materials will be available on the Investor Relations website and referenced during the conference call [2][4] Investor Relations - Contact information for investor relations is provided, including names and phone numbers for key personnel [3] - A replay of the conference call will be accessible starting at 11:00 a.m. ET on November 6, 2025, and will remain available for one year [2][4]

Core Insights - The London Company Small Cap Strategy reported a 1.9% appreciation in its small-cap portfolio for Q3 2025, underperforming the Russell 2000 Index which gained 12.4% [1] - Haemonetics Corporation (NYSE:HAE) was highlighted as a bottom performer, with a one-month return of 1.45% and a significant 31.63% decline over the past 52 weeks [2][3] - The company reported revenue of $321 million in Q1 2026, reflecting a 4% year-over-year decrease [4] Company Performance - Haemonetics Corporation's stock closed at $50.27 on November 3, 2025, with a market capitalization of $2.422 billion [2] - The company is facing competitive pressures in its vascular closure business, which may impact short-term performance [3] - Despite current challenges, the company is expected to leverage its portfolio of high-margin products for future earnings growth [3] Market Position - Haemonetics Corporation was held by 29 hedge fund portfolios at the end of Q2 2025, a decrease from 35 in the previous quarter [4] - The investment community acknowledges the potential of Haemonetics but sees greater upside in certain AI stocks [4]

Core Insights - The third-quarter 2025 investor letter from Aristotle Capital Boston, LLC indicates that U.S. small/mid-cap equities performed well, with the strategy returning 2.57% net of fees, underperforming the Russell 2500 Index's 9.00% total return [1] Company Overview - Haemonetics Corporation (NYSE:HAE) is a medical technology company focused on hematology and blood management products and solutions [3] - As of October 31, 2025, Haemonetics had a market capitalization of $2.409 billion, with shares closing at $50.01 [2] Financial Performance - Haemonetics reported a one-month return of 0.93% but experienced a significant decline of 31.99% over the past 52 weeks [2] - The company reported revenue of $321 million in the first fiscal quarter of 2026, reflecting a 4% decrease year-over-year [4] Analyst Insights - The company beat analyst earnings estimates but fell short on revenue expectations during the quarter [3] - Despite the mixed results, the company is viewed positively due to its strong competitive position in the plasmapheresis market and increased investment in research and development, which is expected to create long-term shareholder value [3]

Core Points - Haemonetics Corporation plans to release its second quarter fiscal year 2026 financial results on November 6, 2025, at 6:00 am ET [1] - A conference call for investors and analysts will take place on the same day at 8:00 am ET to discuss the results [1] Financial Results Announcement - The financial results will be published on November 6, 2025, at 6:00 am ET [1] - The conference call will provide an opportunity for discussion and Q&A regarding the financial results [1] Access Information - Participants can access the call via teleconference after completing registration, which provides a dial-in number and personalized PIN [2] - A live webcast of the call will be available on Haemonetics' investor relations website [2] - A replay of the conference call and webcast will be accessible for one year starting from November 6, 2025, at 11:00 am ET [2] Company Overview - Haemonetics is a global medical technology company focused on enhancing healthcare quality, effectiveness, and efficiency [3] - The company offers innovative solutions for hospital technologies, plasma collection, and blood component collection [3]

Core Insights - Haemonetics Corporation is identified as one of the most oversold healthcare stocks in 2025, focusing on blood and plasma management technologies to enhance healthcare efficiency through innovative medical devices [1] Group 1: Product Launch and Innovation - In 2025, Haemonetics launched the PerQseal Elite vascular closure system, which received European CE Mark approval. This device is fully bioresorbable and sutureless, designed for large-bore vascular access sites used in procedures like TAVR and EVAR [2] - The PerQseal Elite device deploys from inside the vessel, leaving no residual materials, thus restoring the vessel to its natural state and improving procedural control. This launch reflects a trend towards minimally invasive, bioresorbable devices that enhance patient outcomes and procedural efficiency [2] Group 2: Financial Performance - Haemonetics reported its first-quarter fiscal 2026 results on August 7, 2025, with an earnings per share (EPS) of $1.10, exceeding analyst estimates by $0.09. However, revenue declined by 4.4% year-over-year to $321.39 million [3] - Despite the revenue decline, the company demonstrated resilience in profitability and operational performance, indicating its capability to navigate challenging market conditions [3] Group 3: Leadership and Strategic Focus - In early 2025, Haemonetics made strategic leadership appointments, including Frank Chan as Executive Vice President and Chief Operating Officer, and Roy Galvin as Executive Vice President and Chief Commercial Officer. These appointments aim to strengthen operational excellence and expand commercial reach [4]

Core Insights - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors [1] Group 1 - The analysis occasionally includes large-cap companies to provide a broader perspective on equity markets [1]

Core Insights - Haemonetics' international operations are crucial for assessing its financial resilience and growth prospects, especially in a tightly interconnected global economy [2][3] - The company's total revenue for the quarter ended June 2025 was $321.39 million, reflecting a year-over-year decline of 4.4% [4] International Revenue Breakdown - Japan generated $13.65 million in revenue, accounting for 4.3% of total revenue, which was a surprise decline of 14.62% compared to the expected $15.99 million [5] - The Rest of Asia contributed $21.65 million, representing 6.7% of total revenue, with a surprise decline of 7.55% from the expected $23.42 million [6] - Europe accounted for $40.88 million, or 12.7% of total revenue, with a surprise decline of 10.32% from the anticipated $45.59 million [7] Revenue Forecasts - Analysts expect Haemonetics to report $321.11 million in total revenue for the current fiscal quarter, indicating a decline of 7.1% from the previous year [8] - For the full year, total revenue is projected to be $1.3 billion, down 4.2% from the previous year, with Japan, Rest of Asia, and Europe expected to contribute 5.4% ($70.72 million), 8.3% ($108 million), and 13.9% ($181.38 million) respectively [9] Market Dynamics - The reliance on foreign markets presents both opportunities and challenges for Haemonetics, necessitating close monitoring of international revenue trends to project future performance [10] - The company's stock has seen a significant decline of 28.5% over the past four weeks, contrasting with a 2.7% increase in the S&P 500 [13]

Group 1 - Haemonetics Corp reported quarterly earnings of $1.10 per share, exceeding the analyst consensus estimate of $1.02 per share [1] - The company reported quarterly sales of $321.394 million, surpassing the analyst consensus estimate of $305.115 million [1] - Haemonetics affirmed FY2026 adjusted EPS guidance of $4.70 to $5.00 [1] - Haemonetics shares closed at $55.63 on the day of the earnings announcement [1] Group 2 - JP Morgan analyst downgraded Haemonetics from Overweight to Neutral and lowered the price target from $85 to $62 [4] - Mizuho analyst maintained an Outperform rating on Haemonetics but lowered the price target from $90 to $70 [4] - Barrington Research analyst also maintained an Outperform rating while lowering the price target from $95 to $86 [4]

Core Insights - Haemonetics reported revenue of $321.39 million for the quarter ended June 2025, reflecting a year-over-year decline of 4.4% [1] - The earnings per share (EPS) for the same period was $1.10, compared to $1.02 a year ago, indicating an increase [1] - The reported revenue exceeded the Zacks Consensus Estimate of $303.28 million by 5.97%, while the EPS surpassed the consensus estimate of $1.01 by 8.91% [1] Revenue Breakdown - Plasma segment net revenues were $129.9 million, exceeding the average estimate of $113.65 million by three analysts, but showing a year-over-year decline of 4.4% [4] - Hospital segment net revenues reached $139.66 million, slightly below the average estimate of $144.4 million, with a year-over-year increase of 4.2% [4] - Blood Center segment net revenues were $51.84 million, surpassing the average estimate of $46.38 million, but reflecting a significant year-over-year decline of 21.8% [4] Stock Performance - Haemonetics shares have returned -2.3% over the past month, contrasting with the Zacks S&P 500 composite's increase of 1.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported revenue of $321 million, down 4% due to a $52 million impact from portfolio transitions, but up 13% organically excluding CSL [8][16] - Adjusted EPS grew 8% to $1.10, driven by strong growth in the base business and share buybacks [8][19] - Adjusted gross margin reached 60.8%, up 550 basis points year over year, supported by technology benefits and a favorable product mix [18][19] Business Line Data and Key Metrics Changes - The hospital business generated $140 million in revenue, up 4% reported and organically, with Blood Management Technologies growing 14% [10][12] - Plasma revenue was $130 million, down 4% reported but up 29% organically, driven by technology upgrades and a one-time revenue benefit from a software agreement [12][14] - Interventional technologies declined 7% due to tough comparisons from prior year OEM destocking [11][12] Market Data and Key Metrics Changes - The U.S. plasma collection volume grew in the low single digits, with expectations for modest recovery in the back half of the fiscal year [13][82] - The company maintains an 80% market share in plasma DMS software, reinforcing its competitive position [13][30] Company Strategy and Development Direction - The company is focused on strengthening its core products: plasma, hemostasis management, and vascular closure, which are expected to drive revenue growth and margin expansion [23][24] - Strategic initiatives include leadership additions, organizational realignment, and targeted commercial initiatives to enhance execution in interventional technologies [9][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance, with expectations for low double-digit compounded annual growth in revenue and mid-20s adjusted EPS CAGR [22][23] - The company anticipates stronger cash generation and reaffirmed full-year free cash flow guidance of $160 million to $200 million [21][22] Other Important Information - The company completed $225 million in share buybacks last year and has authorized a new $500 million program for the next three years [75] - The adjusted income tax rate was 24.9% in the quarter, up from 19.9% the previous year, reflecting lower benefits from performance share vestings [19] Q&A Session Summary Question: Can you provide details on the drivers of strong plasma performance? - Management highlighted innovation in pricing and share gains, with half of the 29% growth attributed to a software agreement [28][30] Question: What is the growth rate for MVP and MVP XL in vascular closure? - MVP and MVP XL saw roughly 6% growth, with challenges noted in the legacy Vascade product [34][36] Question: What is the outlook for U.S. plasma collections? - Management indicated a possibility of low single-digit growth in the back half of the year, with ongoing share gains expected [82][84] Question: How is the company addressing increased competition in interventional technologies? - The company is enhancing its sales and marketing efforts, reorganizing teams, and focusing on execution to regain competitiveness [71][72] Question: What is the company's appetite for further M&A? - Management stated that M&A is off the table in the near term, focusing instead on improving existing business performance [76]